PUBLISHED ASSESSMENT

Flu Vaccine Safety | Influenza (Flu) | CDC

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Historical provenance limit: this assessment has a recorded retrieval URL from before Beaconwright’s current publisher-verification boundary. It has not been reverified under the current boundary.

Open original article

The principal safety claims are strongly supported by surveillance and cohort evidence. The page handles common effects, rare severe reactions, GBS uncertainty, and VAERS limitations responsibly. Its main weaknesses are simplified contraindication language, limited quantitative risk context, and a lack of direct study citations in the supplied text. Updated product-specific guidance should be incorporated.

Evidence support

Strong (84/100)

Large surveillance studies and current CDC guidance support the central safety claims.
Research supports the stated small GBS risk and the higher risk following influenza illness.
Pregnancy-safety findings are supported by large cohort evidence.
The categorical allergy restriction is less nuanced than current product-specific guidance.

Balance & context

Substantial (78/100)

The page discusses common reactions, GBS, anaphylaxis, contraindications, compensation, and surveillance limitations.
It appropriately explains that VAERS reports generally cannot establish causation.
It does not quantify anaphylaxis risk or discuss some uncommon signals such as febrile seizures.
Contraindications and precautions are simplified rather than differentiated by vaccine formulation.

Transparency

Substantial (74/100)

The responsible agency and publication date are clearly identified.
Named surveillance systems and government programs are linked.
Uncertainty concerning GBS and VAERS causality is stated explicitly.
Broad safety assertions are not accompanied by direct study citations or accessible methods in the supplied text.

Confidence and coverage

Confidence in this analysis: High confidence

Evidence coverage: Substantial coverage

The supplied 2023 text does not expose its underlying study list.
Evidence for every vaccine formulation and age group was not reviewed.
Recommendations have changed since publication, including 2025–2026 contraindication guidance.

Multiple official recommendations and large observational studies were accessible.
The principal claims are specific and independently testable.
Some formulation-specific evidence and the page's original source list were unavailable in the supplied material.

Sources considered

Prevention and Control of Seasonal Influenza with Vaccines: United States, 2025–26 Influenza Season — Current guidance provides more nuanced, formulation-specific precautions after severe allergic reactions than the article's categorical wording.
Guillain-Barré Syndrome and Flu Vaccine — Supports the estimated one-to-two additional GBS cases per million doses and explains seasonal uncertainty.
Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters — Found a much lower attributable GBS risk after vaccination than after influenza-related healthcare encounters.
Influenza Vaccination During Pregnancy: Influenza Seasons 2002–2012, Vaccine Safety Datalink — Provides large-cohort evidence concerning influenza-vaccination safety during pregnancy.
Safety monitoring following influenza vaccination during the 2023–2024 season — Recent active surveillance found a small febrile-seizure signal, illustrating an uncommon risk omitted from the page.
Anaphylaxis After Vaccination in Children and Adults — Supports the characterization of vaccine-associated anaphylaxis as rare and provides an absolute risk estimate.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-09-12 (current)	84	78	74